Clinical Trial Update: Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of novel anti-CD19 universal CAR-T cells for relapsed/refractory CD19+ B-cell acute lymphoblastic leukemia (B-ALL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-all
• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• universal anti-CD19 CAR-T cells (anti-CD19 universal CAR-T cells)

Snippet

Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Conditions: B-cell Acute Lymphoblastic Leukemia, B-ALL | Phase 1, Phase 2 | Status: UNKNOWN